Geftinat (Gefitinib) 250 mg
Geftinat is an oral targeted therapy medication containing Gefitinib (250 mg).
Manufacturer: Natco Pharma (India). It is a high-quality generic equivalent of Iressa.
Precision Medicine:
Geftinat is an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor. It works by blocking the signaling pathways that tell cancer cells to grow. It is specifically designed for patients whose tumors have specific EGFR mutations.
✅ Key Benefit: Offers a pill-based alternative to chemotherapy with fewer severe side effects for eligible patients.
Indicated for the treatment of adult patients with Non-Small Cell Lung Cancer (NSCLC):
- First-line treatment: For patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
- Subsequent treatment: For patients with continued disease progression after platinum-based chemotherapy.
Standard Dosage: One 250 mg tablet once daily.
⚠️ Administration Instructions:
- Can be taken with or without food.
- Take at approximately the same time each day.
- Difficulty swallowing? The tablet can be dispersed in half a glass of drinking water (do not crush it). Stir until dispersed and drink immediately.
🚫 Drug Interaction Warning: Avoid drugs that reduce stomach acid (PPIs like Omeprazole, H2-blockers), as they significantly reduce Geftinat absorption.
- Hypersensitivity to Gefitinib.
- Pregnancy and breastfeeding.
- Severe hepatic impairment.
- Patients known to be EGFR mutation-negative (lack of efficacy).
Common side effects (often manageable):
- Skin Rash (Acneiform): Very common. Indicates the drug is potent. Managed with topical antibiotics or moisturizers.
- Diarrhea: Usually mild to moderate.
- Paronychia: Nail bed infections or brittle nails.
- Dry skin.
What Customers Say
No reviews yet
Your review can be the first!